Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Xijing Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00666783 | https://clinicaltrials.gov/study/NCT05134519 | https://clinicaltrials.gov/study/NCT07466303
Assets
Linked programs
- palonosetron: Results Not Found Signal (3/5)
- Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC): Timeline Staleness Signal (3/5)
- Serplulimab: Low Signal (0/5)